Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Conditions
- Lymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage III Hodgkin LymphomaClassic Hodgkin LymphomaAnn Arbor Stage III Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage IV Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Hodgkin Lymphoma
- Interventions
- Procedure: Biospecimen CollectionDrug: Brentuximab VedotinProcedure: Computed TomographyDrug: DacarbazineDrug: Doxorubicin HydrochlorideBiological: FilgrastimProcedure: Magnetic Resonance ImagingBiological: NivolumabBiological: PegfilgrastimProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation TherapyDrug: Vinblastine Sulfate
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 995
- Registration Number
- NCT03907488
- Locations
- 🇺🇸
Corewell Health Beaumont Troy Hospital, Troy, Michigan, United States
🇺🇸Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan, United States
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT03755804
- Locations
- 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 40
- Registration Number
- NCT03719105
- Locations
- 🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸Helen De Vos, Grand Rapids, Michigan, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
- Conditions
- Ann Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage I Lymphocyte-Depleted Classic HLAnn Arbor Stage II Hodgkin LymphomaLymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage II Mixed Cellularity Classic HLAnn Arbor Stage II Nodular Sclerosis Classic HLAnn Arbor Stage I Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 155
- Registration Number
- NCT03712202
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 21
- Registration Number
- NCT03652441
- Locations
- 🇩🇪
1st Department of Medicine, Cologne University Hospital, Cologne, Germany
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT03646123
- Locations
- 🇺🇸
Texas Oncology - Flower Mound, Flower Mound, Texas, United States
🇺🇸Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States
🇨🇿Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Other, Czechia
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- Conditions
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT03587844
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2019-11-18
- Target Recruit Count
- 220
- Registration Number
- NCT03527628
- Locations
- 🇸🇦
King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 150
- Registration Number
- NCT03517137
- Locations
- 🇳🇱
Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇵🇱Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2020-07-21
- Target Recruit Count
- 80
- Registration Number
- NCT03474133
- Locations
- 🇷🇺
City clinical hospital №40, Moscow, Russian Federation
🇷🇺R. Gorbacheva Research Institute of Pediatric Hematology and Transfusiology; Pavlov State Medical University of Saint-Petersburg, Saint Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.